Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from its Phase 1/2 trial of Z-1018, the company’s experimental shingles vaccine ...

GlaxoSmithKline PLC GSK 0.79% has reported positive results from a study of a cancer drug in a clinical trial that a senior figure in the company said justified the decision to acquire cancer ...

GSK plc has announced the acquisition of American Depositary Shares (ADSs) by two of its executives, Dr. Hal Barron and James Ford, through reinvestment of dividends in their respective savings plans.

In conclusion, GlaxoSmithKline's shares showed significant gains today, reflecting positive market sentiment and strong ...

Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs for its inhalers at $35 a month, Sen. Maggie Hassan (D-N.H.) is accusing the company of circumventing that vow through ...

GlaxoSmithKline’s (GSK) materially understated profits and alarming and material disclosures in the 10-Ks of Squarespace (SQSP), VBI Vaccines (VBIV), and Research Frontiers (REFR).

July 14, 2010 -- In the face of mounting evidence that GlaxoSmithKline withheld important safety data on their controversial drug Avandia, some doctors are abandoning use of this diabetes treatment.

Zachary Easterly was fired from his job as an engineer at GlaxoSmithKline after videos emerged showing him yelling racist and homophobic slurs while being removed from a flight in Philadelphia.

GlaxoSmithKline is cutting employees in China, as the U.K. drug company grapples with accusations from Beijing that it bribed doctors and officials to boost sales.

GlaxoSmithKline's chief executive officer said in an email to the company’s employees that Slaoui’s name would be removed from its research and development facility in Rockville, Md.

GlaxoSmithKline (GSK-0.81%) has confirmed plans to separate its consumer and pharmaceutical business units. However, an activist investor appears to want the big drugmaker to take more drastic ...

GlaxoSmithKline is accused in a lawsuit of using threats to block generic competition to its $2-billion-a-year antibiotic Augmentin after a U.S. judge eliminated the drug's patent protection.